- Home
- EYPT vs VRE Comparison
EYPT vs VRE Comparison
Compare EYPT & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | VRE |
|---|---|---|
| Founded | 1987 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate Investment Trusts |
| Sector | Industrials | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EYPT | VRE |
|---|---|---|
| Price | $15.19 | $14.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.75 | $18.67 |
| AVG Volume (30 Days) | ★ 907.6K | 592.8K |
| Earning Date | 03-04-2026 | 02-23-2026 |
| Dividend Yield | N/A | ★ 2.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | $42,339,000.00 | ★ $291,348,000.00 |
| Revenue This Year | N/A | $4.85 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.79 |
| Revenue Growth | N/A | ★ 6.39 |
| 52 Week Low | $3.91 | $13.69 |
| 52 Week High | $19.11 | $17.18 |
Technical Indicators
Market Signals| Indicator | EYPT | VRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 47.50 |
| Support Level | $14.62 | $14.61 |
| Resistance Level | $16.73 | $15.23 |
| Average True Range (ATR) | 1.03 | 0.32 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 21.30 | 29.26 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.